Europe's largest listed company, Novo Nordisk (NOVOB.DK) is gaining nearly 2% in today's session following decisions by the FDA and the US patent office. A tribunal of the U.S. patent office rejected a request by Mylan Pharmaceuticals to review the validity of patents held by Novo on the main active ingredients in Wegova and Ozempic. What's more, the FDA, or U.S. Food and Drug Administration, has approved Novo Nordisk's making a proprietary therapy to treat a rare genetic defect of the kidneys.
The drug will be given by injection under the brand name Rivfloza. The therapy is to be priced according to the clinical value and benefit of people struggling with the disease, the company added. There may be more than 2,000 such individuals (suffering from hyperoxaluria) in the US, the company added.
Source: xStation 5
Abbott reports no surprises in Q3, but tariff risks and lowered forecasts drag the share price down💡
DE40: Good earnings and cautious optimism
OpenAI announces an ambitious $1 trillion investment plan
LVMH surprises with its earnings. Is fashion back in favor with investors❓
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
